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Background. The immunomodulatory nutritional product NR100157 was developed for human immunodeﬁ-
ciency virus (HIV)–infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of
HIV-infected individuals would result in systemic immunological beneﬁts.
Methods. In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1–positive adults not on antire-
troviral therapy, with CD4+ T-cell counts <800/µL, were given either NR100157 or an isocaloric and isonitrogenous
control for 52 weeks. Primary outcome was CD4+ T-cell count. Secondary outcomes included plasma viral load
(pVL), safety, and tolerability. In a pilot study (n = 20), levels of CD4+CD25+ and CD8+CD38+ activation were mea-
sured (n = 20). The trial is registered at the Dutch Trial Register (NTR886) and ISRCTN81868024.
Results. At 52 weeks, CD4+ T-cell decline showed a 40-cell/µL difference (P = .03) in the intention-to-treat pop-
ulation in favor of the immunomodulatory NR100157 (control vs active, −68 ± 15 vs −28 ± 16 cells/µL/year). The
change in pVL from baseline was similar between groups (P = .81). In the pilot study, the percentage of CD4+CD25+
was lower in the active group (P < .05) and correlated with changes in CD4+ T-cell count (r =−0.55, P < .05). The
percentage of CD8+CD38+ levels was unaffected.
Conclusions. The speciﬁc immunonutritional product NR100157 signiﬁcantly reduces CD4+ decline in HIV-
1–infected individuals, and this is associated with decreased levels of CD4+CD25+. (This nutritional intervention is
likely to affect local gut integrity and gut-associated lymphoid tissue homeostasis, which in turn translates positively
to systemic effects.)
Clinical Trials Registration. ISRCTN81868024.
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Loss of plasma CD4+ T cells [1] is a hallmark of human immu-
nodeﬁciency virus (HIV) infection. Residual immune activa-
tion in relation to CD4+ T-cell depletion in HIV-infected
persons is increasingly recognized [2, 3]. HIV infection is asso-
ciated with a rapid loss of gut-associated CD4+ T cells, im-
paired function of epithelial cells, and alterations in the
composition of the gut microbiota, leading to a loss of gastroin-
testinal (GI) homeostasis and barrier function [4, 5]. Residual
immune activation persists even in patients on stable antiretro-
viral (ARV) treatment, and this is increasingly linked to non-
AIDS events such as cardiovascular disease and liver and
kidney toxicities [6]. Moreover, the efﬁcacy of ARV treatment
in the GI tract appears less effective, as shown by the incom-
plete restoration of CD4+ T-cell counts [7, 8] and incomplete
viral suppression, leading the GI tract to function as a viral res-
ervoir with low levels of ongoing viral replication [7, 9]. As a con-
sequence of a compromised gut, bacteria or bacterial products
can translocate and enter the circulation, and these have
been suggested to contribute to immune activation. In HIV-1–
infected individuals, increased markers of bacterial translocation
have been reported and have been correlated with parameters of
immune activation and disease progression [10]. In patients on
highly active ARV therapy (HAART), markers of bacterial trans-
location also correlate with immune activation and lower levels
of CD4+ T-cell restoration [11]. These data support the hypothe-
sis that the GI tract plays a major role in HIV-induced chronic
immune activation [12]. Immune activation in HIV-infected pa-
tients has been reported to be a stronger predictor of disease pro-
gression than viral load or CD4+ count [13].
Disturbance of intestinal microbiota composition occurs early
after HIV infection [4], and intervention with prebiotic oligosac-
charides can help normalize microbiota. The components in the
immunomodulatory nutritional product NR100157 are listed in
Table 1. The speciﬁc oligosaccharides in NR100157 have been
shown to enhance T-helper 1–dependent immune responses
and increase resistance to infection in a murine inﬂuenza vacci-
nation model and in infants [14, 15] and to reduce markers of
immune activation in HIV-1–infected patients [16]. A higher in-
ﬂammatory state of the gut mucosa has been found in many in-
fected with HIV, with evidence that intestinal inﬂammation is a
direct consequence of HIV infection [17, 18]. Long-chain n-3
and n-6 polyunsaturated fatty acids induce anti-inﬂammatory
effects by reducing the production of arachidonic acid–derived
inﬂammatory mediators [19, 20]. Substantial data demonstrate
that intestinal integrity is compromised in HIV-1 infection, and
bovine colostrum has reportedly aided in decreasing permeabili-
ty [21]. Glutathione depletion is observed in HIV-infected indi-
viduals and is associated with impaired survival [22] as well as
with perturbations of immune responses [23].
Taking this evidence into account, together with the fact that
HIV may initiate a complex dysregulation of metabolism
associated with changes in nutritional status, lipid metabolism,
and immune function, NR100157 was designed to target the
gut. It was hypothesized that NR100157 could beneﬁcially
affect the health status of HIV-infected individuals by support-
ing gut integrity and immune function because beneﬁcial
effects in the gut would translate to preservation of plasma
CD4+ count. The target population was HIV-1–infected pa-
tients not on ARV treatment.
METHODS
Study Design
A multicenter, multinational, randomized, controlled, double-
blind trial (ISRCTN81868024; BITE), with 52 weeks of inter-
vention, was conducted between March 2007 and July 2009.
Eligible participants were HIV-1–infected adults (aged >18 years)
not on ARV therapy who were enrolled from 30 sites in 8 coun-
tries worldwide: Italy (3 sites), the Netherlands (4 sites), the
United Kingdom (3 sites), Thailand (1 site), United States (6
sites), Brazil (4 sites), Argentina (4 sites), and Australia (5
sites). The protocol included an interim analysis after 340 ran-
domized participants completed the 52-week supplementation
period. Protocol and consent forms were approved by the
ethics review committee at each site. A pilot study of 20 patients
was performed at 1 site to study CD4+ and CD8+ T-cell activa-
tion. Written informed consent was obtained from all individu-
als before study participation.
Table 1. Product Composition: Intake Per Day (2 Doses)
Ingredient Active Control
Energy 314 kcal 314 kcal
Total lipids 7.4 g 7.4 g
EPA 1.24 g . . .
DHA 0.65 g . . .
GLA 0.49 g . . .
Total protein 16.4 g 16.4 g
Bovine colostrum protein 12.5 g . . .
Cysteine from (1.8 g) NAC 1.3 g . . .
Cysteine (total) 1.6 g 0.1 g
Total carbohydrates 40.2 g 45.8 g
Lactose 6.9 g 6.9 g
Glucose 0.1 g 0.3 g
Oligosaccharides 15.0 g . . .
Short-chain GOS 6.75 g . . .
Long-chain FOS (inulin) 0.75 g . . .
Pectin-derived AOS 7.50 g . . .
Abbreviations: AOS, acidic oligosaccharides; DHA, docosahexaenoic acid;
EPA, eicosapentaenoic acid; FOS, fructo oligosaccharides; GLA, γ-linolenic
acid; GOS, galacto oligosaccharides; NAC, N-acetyl cysteine.
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The time to ART initiation for the participants who dropped
out of the study due to commencement of therapy was plotted
retrospectively.
Study Outcomes
The primary outcome of the trial was the change from baseline
in plasma CD4+ T-cell count. Plasma concentrations of HIV-1
RNA, CD8+ cell count, % CD4+, % CD8+, and the CD4+/CD8+
ratio were assessed as secondary parameters at baseline and at
weeks 13, 26, 39, and 52. All laboratory and clinical assessments
were performed blinded at the participating centers. CD4+ and
CD8+ T-cell counts were performed using ﬂow cytometry.
Plasma HIV-1 RNA levels were quantiﬁed using the Amplicor
HIV-1 monitor test, NucliSens HIV-1 QT, or Quantiplex HIV-
1 RNA. Adherence was assessed using patient diaries that were
checked against the returned sachets. GI tolerance was assessed
using a questionnaire and scoring the severity of GI symptoms
within a 4-point scale.
Statistical Analyses
The power calculation was based on published longitudinal
CD4+ T-cell data, predicting a decline of 50–70 cells/µL per
year [1]. Combined with an anticipated dropout rate of 25%, a
power of 80%, and an alpha of 0.05, this led to an initial sample
size calculation of 800 patients. A protocol-planned interim
analysis was performed when full data would become available
for 340 participants. An independent data and safety monitor-
ing board (DSMB) reviewed the results of the blinded interim
analysis. In accordance with predeﬁned stopping rules, the trial
was stopped and arms unblinded due to high rates of loss to
follow-up. All data presented in this paper, including graphs
and tables, and all statistical analyses were performed on the in-
tention-to-treat (ITT) population, unless stated otherwise. Log-
arithmic transformation was used to normalize the distribution
of CD4+ T-cell count, viral load, % CD4+ T-cell count, aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT),
creatinine, prothrombin time, hemoglobin, white blood cell
count, lymphocytes, and neutrophils.
To analyze efﬁcacy and safety, differences between the 2
study arms were compared using repeated measures mixed
models. The SPSS statement REPEATED was used to model
the covariance among the repeated measures obtained on the
same participants with the structure compound symmetry.
Study site was entered as a random effect (statement
RANDOM) with a covariance structure identity. In these
models, a response proﬁle analysis was used to describe the
mean response over time, allowing a study arm comparison at
each measurement occasion. In addition, the mean response
over time was modeled with a linear trend (ﬁrst-order polyno-
mial). The signiﬁcance of the study arm by time coefﬁcient
indicates the overall intervention effect that can be interpreted
as a difference in slopes.
GI tolerability questionnaires were analyzed using cross
table statistics, comparing the 2 groups. Values are reported
as estimated marginal mean ± SE, unless stated otherwise.
All analyses were performed using SPSS software, version
15.0.1 or higher, and statistical signiﬁcance was reached
when P < .05.
Role of the Funding Source
Nutricia Advanced Medical Nutrition designed the study and
collected and analyzed the data. Local investigators were in-
volved in sample collection. The study report was written by
the study sponsor. The publication coauthors made the deci-
sion to submit the paper for publication. The corresponding
author conﬁrms that he had full access to all data in the study
and had ﬁnal responsibility for the decision to submit for
publication.
RESULTS
Study Population
Of the 409 participants who were screened in the study, 69
were not eligible and 340 underwent randomization at 1 of the
30 sites. A total of 143 participants completed the full 1-year
study on treatment, 83 in the control and 60 in the active arm
(Figure 1). The baseline characteristics were not signiﬁcantly
different between groups (Table 2). The average compliance to
the product was 85% and similar between active and control
groups (85% and 86%, respectively).
CD4+ T-Cell Count Decline
A signiﬁcant decline in CD4+ T-cell count was observed in the
NR100157 intervention group: the baseline-corrected decline
in CD4+ T-cell count was 28 ± 16 cells/µL in the active group
compared with 68 ± 15 cells/µL in the control group at 52
weeks (Figure 2; P = .030), showing a difference of 40 cells/µL
in favor of the NR100157 group. A similar difference was ob-
served when the slopes of CD4+ T-cell decline over 52 weeks
were compared between the study groups (steeper slope of
decline in the control group compared with the active group,
P = .016) or when the baseline-corrected decline in CD4+ T-cell
count over 52 weeks was analyzed in the group of participants
who completed the study (−18 ± 20 cells/µL in the active
group, −68 ± 17 cells/µL the control group; a difference of 50
cells/µL, P = .014).
HIV-1 RNA and CD4+/CD8+ Ratio and Percentages
Secondary outcomes did not differ signiﬁcantly between the
study groups (see Supplementary Table 1). HIV-1 RNA levels
remained stable during the study; the change from baseline
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was −0.01 ± 0.07 log10 RNA copies/mL in the active group
compared with −0.03 ± 0.07 log10 RNA copies/mL in the
control group at 52 weeks (P = .811; see Supplementary
Figure 1). The baseline-corrected CD8+ cell count was higher
in the active group compared with the control group at 26
weeks (P = .050) but not at 39 weeks (P = .097) or at 52 weeks
(P = .477). Furthermore, % CD4+, % CD8+, and % CD4+/%
CD8+ ratio did not differ between study groups at the different
timepoints (see Supplementary Table 1).
CD4+ and CD8+ T-Cell Activation
A total of 20 individuals (n = 10 per group) were analyzed in a
pilot study for the expression of T-cell activation markers.
Baseline characteristics did not differ between the groups and
were comparable to the characteristics of the total study popu-
lation (see Supplementary Table 2). Three participants
dropped out of the study due to the start of ARV treatment, 1
in the control (>24 weeks) and 2 in the active group (>39
weeks). The effect of the intervention showed trends that were
similar to those seen in the total study population: the decline
in CD4+ T-cell count tended to be less in the active group
(difference at 52 weeks of 77 cells/µL; P = .107), and the
plasma viral load did not differ between groups (see Supple-
mentary Table 2).
CD4+ T-cell activation, measured as baseline-corrected ex-
pression of CD25 on CD3+CD4+CD45+ cells, was signiﬁcantly
higher in the control group than in the active group at week 26
(P = .036; Figure 3). When CD4+ T-cell activation was analyzed
in the participants who completed the study on treatment, this
difference was signiﬁcant at week 26 and week 52 (P = .006 and
P = .048, respectively; data not shown). Moreover, CD4+ T-cell
activation correlated with CD4+ T-cell count at 52 weeks
Table 2. Patient Baseline Characteristics of Study Groups
(Mean ± SD or n [%]); Intention-to-Treat
Variable (Unit)
Control Group
(n = 172)
Active Group
(n = 168)
Sex (n [%]) Male 140 (81%) 139 (83%)
Female 32 (19%) 29 (17%)
Age (y) 40.1 ± 9.7 39.2 ± 9.3
Body mass index (kg/m2) 24.6 ± 3.4 24.4 ± 4.0
Duration of HIV-1 infection from
diagnosis (d)
424 ± 122 413 ± 110
Race: White 142 128
Asian 13 17
Hispanic 9 9
African 3 5
Other 5 9
CD4+ T-cell count (cells/µL) 413 ± 136 425 ± 154
CD8+ T-cell count (cells/µL) 1028 ± 413 1022 ± 419
% CD4+ T cells 23.2 ± 6.8 23.4 ± 7.3
% CD8+ T cells 54.2 ± 9.0 54.1 ± 10.9
Ratio % CD4+/% CD8+ 0.45 ± 0.20 0.47 ± 0.22
Plasma HIV-1 RNA
(log10 copies/mL)
4.53 ± 0.64 4.47 ± 0.60
Medical history (n [%])
HBV 10 (6) 8 (5)
HCV 6 (3) 5 (3)
HBV/HCV status unknown 1 (1) 0 (0)
CDC classification (n [%])
Class A (asymptomatic) 151 (88) 149 (89)
A1 (CD4≥ 500 cells/mm3) 43 (25) 54 (32)
A2 (CD4 200–499 cells/mm3) 105 (61) 89 (53)
A3 (CD4 < 200 cells/mm3) 3 (2) 6 (4)
Class B (symptomatic, not A
or C)
19 (11) 18 (11)
B1 (CD4≥ 500 cells/mm3) 1 (1) 3 (2)
B2 (CD4 200–499 cells/mm3) 18 (11) 14 (8)
B3 (CD4 < 200 cells/mm3) 0 1 (1)
Class C (AIDS indicator) 2 (1) 1 (1)
C2 (CD4 200–499 cells/mm3) 2 (1) 1 (1)
Abbreviations: CDC, Centers for Disease Control and Prevention; HBV,
hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus
type 1.
Figure 1. Trial proﬁle, screening, randomization, and study completion.
Abbreviations: HAART, highly active antiretroviral therapy; ITT, intention-
to-treat.
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(r = 0.552, P = .027). Activation of CD8+ T-cells, as analyzed by
the expression of CD38 on CD3+CD8+CD45+CD45RO+ cells,
was not signiﬁcantly affected by the intervention (see Supple-
mentary Table 2).
No difference was observed in FoxP3 expression between
groups (data not shown).
Reasons for Study Discontinuation
In the active group, 83 patients (49%) dropped out of the study
for reasons other than ARV treatment initiation, compared
with 60 (35%) in the control arm (Figure 1). Loss to follow-up
and withdrawal of informed consent occurred similarly in both
groups. The number of patients with adverse events as the
reason for discontinuation was 30 (18%) in the active group
and 14 (8%) in the control group. Adverse events as the reason
for dropout were GI-related events in 74% of the cases in the
active group and in 57% of the cases in the control group.
ARV treatment initiation was a protocol-deﬁned endpoint of
the study. Although the number of individuals initiating ARV
treatment during the study was not signiﬁcantly different
(n = 25 active vs n = 29 control groups), the average time to
ARV treatment initiation was signiﬁcantly longer in the active
treatment group (230 ± 15 days, n = 25; P = .018) than in the
ARV treatment dropout population receiving the control treat-
ment (167 ± 13 days, n = 29; Figure 4). Baseline CD4+ T-cell
counts were analyzed as a potential confounding factor for the
treatment effect on time to ARV treatment initiation. However,
neither a signiﬁcant difference between the 2 groups nor a sig-
niﬁcant correlation between both parameters were observed
(data not shown).
Safety
Ten signiﬁcant adverse events (SAEs) occurred in 9 partici-
pants during the study; 9 SAEs in 8 individuals in the control
group and 1 SAE in 1 individual in the active group. The inves-
tigator considered 2 SAEs in the control group, diarrhea and
non-Hodgkin lymphoma, to be possibly related to the use of
the study product. After consultation with several HIV experts
and the study’s principal investigator, the DSMB classiﬁed
non-Hodgkin lymphoma as being not related (see Supplemen-
tary Table 3 listing of SAEs per study group). There were 513
SAEs in the active group and 489 in the control group. Of
Figure 4. Time until participant study discontinuation due to highly
active antiretroviral therapy therapy (HAART) initiation (population HAART
dropouts; n = 25 for active treatment and n = 29 for control treatment).
Figure 3. Changes from baseline in activated CD4+ T cells (%
CD4+CD25+) during the 52-week intervention period in the intention-to-
treat population from a BITE pilot study (*P = .036, change from baseline).
Figure 2. Change from baseline in CD4+ T-cell count over 52 weeks of
intervention (intention-to-treat population; *P = .03, change from baseline).
Data are estimated marginal mean ± SE.
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these, 42% and 31% were product related in the active and
control group, respectively, showing a higher number of GI
symptoms in the active group (192 vs 140 in control group; see
also Supplementary Table 4). Temporary mild to moderate GI
complaints were noted more frequently in the active group: the
abdominal distention score was signiﬁcantly higher at week 5
(P = .010) and the ﬂatulence score was higher until week 13
(P < .001). Blood safety parameter means were all within refer-
ence ranges, and no grade 3 or 4 abnormalities were reported.
The mean baseline-corrected AST and ALT concentrations in-
creased over time in the active group and reached statistical sig-
niﬁcance at week 52 compared with the control group
(32.3 ± 18.8 [active] vs 27.9 ± 13.6 U/L [control], P≤ .022 and
38.9 ± 26.5 [active] vs 31.7 ± 23.0 U/L [control], P≤ .001, re-
spectively). However, both AST and ALT concentrations re-
mained within normal reference ranges.
DISCUSSION
CD4+ T-cell decline in HIV-1–infected participants not on
ARV treatment was signiﬁcantly reduced with NR100157, a nu-
tritional product speciﬁcally designed to support the GI tract of
HIV-infected patients. In the control group, the rate of CD4+
T-cell decline (68 cells/µL) at 52 weeks was within the expected
range [1, 24]. However, the difference in decline between both
groups was larger (40 cells/µL difference) than anticipated in
the initial sample size calculation.
The reduction of CD4+ T-cell count in the active group was
not accompanied by any effects on viral load, emphasizing that
disease progression is not an exclusive function of HIV replica-
tion. In a small pilot study, a signiﬁcant reduction of CD4+
CD25+ T cells was observed. The signiﬁcant correlation between
CD4+ T-cell activation and CD4+ T-cell decline supports the
potential relevance of this mechanism. A recent 12-week inter-
ventional study with 15 g oligosaccharides per day, the same as
is present in NR100157, showed a signiﬁcant reduction of
CD4+CD25+ T cells accompanied by a signiﬁcant reduction of
soluble CD14 [16]. No clinically relevant safety concerns were
found based on the reported adverse events and blood chemis-
try and hematology parameters. Liver transaminases werewithin
reference values (ALT <45 U/L, AST <40 U/L).
Study limitations included the small sample size of the pilot
study and the high loss to follow-up due to GI events, which re-
sulted in interim termination of the trial. Adverse events ac-
counted for 44 participants dropping out of the complete
study. The most common adverse events were GI complaints,
which were generally increased after intake of both NR100157
and the control product in those who dropped out (data not
shown). Both the control and active products contained lactose.
Even though lactose intolerance was an exclusion criterion
for this study, it is known that the prevalence of lactose
intolerance is higher in HIV-1–infected individuals than in
healthy volunteers [25]. Undiagnosed lactose intolerance
within the study population could also have contributed to the
GI complaints experienced by those in both groups. Moreover,
temporary GI complaints such as ﬂatulence and abdominal dis-
tention can be expected after any diet change. Temporary GI
complaints were reported in the early weeks of the intervention
but disappeared over time in both the ITT population and the
population of those who completed the study while on treat-
ment. A variety of other factors led to study discontinuation,
including initiation of ARV treatment, which has been a proto-
col-deﬁned endpoint, and loss to follow-up. The current efﬁca-
cy results could provide the incentive for higher compliance in
a follow-up study.
The target population in this study was patients who were
not yet receiving ARV treatment. However, current ARV treat-
ment guidelines, whether for the developed or developing
world are moving toward earlier initiation of therapy [26, 27],
which is likely to reduce the size of the target population de-
scribed in this study. In the recent randomized controlled
CORAL trial, hyperimmune bovine colostrum was tested in
HIV-infected patients with suboptimal CD4+ T-cell response
[28]. In that trial, hyperimmune bovine colostrum, similar to
raltegravir, failed to reconstitute CD4+ cell count when used for
intensiﬁcation in virally suppressive ARV therapy. Initial data
from a recent study with probiotics in combination with ARV
treatment in simian immunodeﬁciency virus–infected pigtail
macaques showed enhanced mucosal immunity by reconstitu-
tion of CD4+ T cells in the colon, decrease of CD4+ activation,
and increase in overall functionality of mucosal CD4+ T
cells [29]. Further studies are required to establish whether
NR100157 can be more effective in combination with ARV
treatment than ARV treatment alone in targeting and restoring
the gut-associated lymphoid tissue, reducing persistent local
immune activation, and thereby improving long-term
prognosis.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org/). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
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